Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt

Standard

Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa? / Ring, Hans Christian; Frew, John W.; Thyssen, Jacob P.; Egeberg, Alexander; Thomsen, Simon F.

I: Clinical and Experimental Dermatology, Bind 47, Nr. 8, 2022, s. 1585-1586.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt

Harvard

Ring, HC, Frew, JW, Thyssen, JP, Egeberg, A & Thomsen, SF 2022, 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?', Clinical and Experimental Dermatology, bind 47, nr. 8, s. 1585-1586. https://doi.org/10.1111/ced.15232

APA

Ring, H. C., Frew, J. W., Thyssen, J. P., Egeberg, A., & Thomsen, S. F. (2022). Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa? Clinical and Experimental Dermatology, 47(8), 1585-1586. https://doi.org/10.1111/ced.15232

Vancouver

Ring HC, Frew JW, Thyssen JP, Egeberg A, Thomsen SF. Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa? Clinical and Experimental Dermatology. 2022;47(8):1585-1586. https://doi.org/10.1111/ced.15232

Author

Ring, Hans Christian ; Frew, John W. ; Thyssen, Jacob P. ; Egeberg, Alexander ; Thomsen, Simon F. / Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?. I: Clinical and Experimental Dermatology. 2022 ; Bind 47, Nr. 8. s. 1585-1586.

Bibtex

@article{4a928545f9a443258b566e8ed6a076ce,

title = "Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?",

author = "Ring, {Hans Christian} and Frew, {John W.} and Thyssen, {Jacob P.} and Alexander Egeberg and Thomsen, {Simon F.}",

note = "Funding Information: No funding for the study. JPT is supported by a grant from the Lundbeck Foundation. Funding Information: HCR has received research funding from the Kgl Hofbundtmager Aage Bang Foundation and honoraria as speaker from Leo Pharma. JWF has conducted advisory work for Janssen, Boehringer‐Ingelheim, Pfizer, Kyowa Kirin, LEO Pharma, Regeneron, Chemocentryx, AbbVie and UCB, participated in trials for Pfizer, UCB, Boehringer‐Ingelheim, Eli Lilly, CSL and Janssen, and received research support from Ortho Dermatologics and Sun Pharma. JPT is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi‐Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi‐Genzyme, and received research grants from Pfizer, Regeneron and Sanofi‐Genzyme. AE has received research funding from Pfizer, Eli Lilly, Novartis, Bristol‐Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd. Gal{\'a}pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co. Ltd. Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol‐Myers Squibb, and Janssen Pharmaceuticals. SFT has been a speaker and/or served on advisory boards for AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB, and has received research support from AbbVie, Janssen, LEO Pharma, Novartis, Sanofi and UCB. The authors declare that they have no conflict of interest. ",

year = "2022",

doi = "10.1111/ced.15232",

language = "English",

volume = "47",

pages = "1585--1586",

journal = "Transactions of the St. John's Hospital Dermatological Society",

issn = "0307-6938",

publisher = "Wiley-Blackwell",

number = "8",